SMARCB1 and chordoma: Moreover, the correlation between clinical responses to nivolumab and immunogenic recognition of brachyury in INI1-deficient pediatric chordomas, as articulated by Williamson et al. [23], provides valuable insights into the immunogenomic landscape of chordomas.